Teva Pharmaceutical Industries Ltd.'s fremanezumab is the third calcitonin gene-related peptide (CGRP) inhibitor to successfully complete a Phase III clinical trial, but two candidates from competing big pharma companies are poised to take first and second place in the race to approval for a blockbuster migraine prevention therapy. That means Teva must exploit a key differentiating feature of its antibody for a potential win in the commercial market.
The company reported on May 31 that both doses of fremanezumab tested in the Phase III HALO CM trial provided...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)